NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

FINANCIAL STATEMENTS 31 DECEMBER 2022

NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 DECEMBER 2022

Contents

Page

Statement of financial position

1

Statement of profit or loss and other comprehensive income

2

Statement of changes in equity

3

Statement of cash flows

4

Notes to the financial statements

5 - 44

Other national disclosures:

Statement of value added

45

Financial summary

46

NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE PERIOD ENDED 31 DECEMBER 2022

3 Months

15 Months

12 Months

ended

ended

ended

% G+(-)

31-Dec-22

31-Dec-22

30-Sep-21

Note

N'000

N'000

N'000

Turnover

8

946,300

3,649,153

3,046,661

20%

Cost of sales

9

(674,273)

(2,275,001)

(1,601,458)

42%

Gross profit / (Loss)

272,027

1,374,152

1,445,203

-5%

Other income

10

9,774

35,938

202,023

-82%

Marketing and distribution expenses

11

(179,430)

(755,772)

(579,694)

30%

Administrative expenses

12

(172,560)

(749,293)

(513,938)

46%

Exchange Gain / (Loss)

13

(90,663)

6,224

(93)

-6792%

Operating (Loss) / Profit

(160,852)

(88,749)

553,501

-116%

Finance costs

14

(19,455)

(201,221)

(188,216)

7%

(Loss) / Profit before taxation

(180,307)

(289,972)

365,285

-179%

Income tax expense

28

-

-

(94,708)

-100%

(Loss)/Profit for the year from continued operation

-

180,307

-

289,972

270,577

-207%

Other comprehensive income

Gain on available for sale assets

-

-

Total other comprehensive income

-

-

-

Total comprehensive (Loss)/Profit

(180,307)

(289,972)

270,577

-207%

Basic (loss)/earnings per share

32

-9%

(15)

14.25

The explanatory notes and statement of significant accounting policies form an integral part of these financial statements.

1

NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

STATEMENT OF CHANGES IN EQUITY

FOR THE PERIOD ENDED 31 DECEMBER 2022

Ordinary

Share

Retained

shares

premium

earnings

Total equity

N'000

N'000

N'000

N'000

At 1 October 2020

949,579

112,606

212,476

1,274,661

Changes in equity the year

Profit for the year

-

-

270,576

270,576

Other comprehensive income

-

-

-

-

Total comprehensive profit for the year

-

-

270,576

270,576

Dividend declared and paid

-

-

(123,445)

(123,445)

Transaction costs for equity issue

-

(7,726)

-

(7,726)

At 30 SEPTEMBER 2021

949,579

104,880

359,608

1,414,067

At 1 October 2021

949,579

104,880

359,608

1,414,067

Changes in equity for the Period

Loss for the year

-

-

(289,972)

(289,972)

Other comprehensive income

-

-

-

-

Total comprehensive Loss for the quarte

-

-

(289,972)

(289,972)

Dividend declared and paid

-

-

(132,941)

(132,941)

Transaction costs for equity issue

-

(96,060)

-

(96,060)

At 31 December 2022

949,579

8,820

(63,305)

895,094

3

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Disclaimer

Neimeth International Pharmaceuticals plc published this content on 30 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 January 2023 15:13:09 UTC.